Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

User Preferences and Persona Design for an mHealth Intervention to Support Adherence to Cardiovascular Disease Medication in Singapore: A Multi-Method Study.

Haldane V, Koh JJK, Srivastava A, Teo KWQ, Tan YG, Cheng RX, Yap YC, Ong PS, Van Dam RM, Foo JM, Müller-Riemenschneider F, Koh GC, Foong PS, Perel P, Legido-Quigley H.

JMIR Mhealth Uhealth. 2019 May 28;7(5):e10465. doi: 10.2196/10465.

2.

Perspectives on Acceptance and Use of a Mobile Health Intervention for the Prevention of Atherosclerotic Cardiovascular Disease in Singapore: Mixed-Methods Study.

Haldane V, Tan YG, Teo KWQ, Koh JJK, Srivastava A, Cheng RX, Yap YC, Ong PS, van Dam RM, Foo JM, Müller-Riemenschneider F, Koh GC, Perel P, Legido-Quigley H.

JMIR Mhealth Uhealth. 2019 Mar 14;7(3):e11108. doi: 10.2196/11108.

3.

Access and adherence to medications for the primary and secondary prevention of atherosclerotic cardiovascular disease in Singapore: a qualitative study.

Koh JJK, Cheng RX, Yap Y, Haldane V, Tan YG, Teo KWQ, Srivastava A, Ong PS, Perel P, Legido-Quigley H.

Patient Prefer Adherence. 2018 Nov 22;12:2481-2498. doi: 10.2147/PPA.S176256. eCollection 2018.

4.

A Review on Liquid Chromatography-Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs.

Wong AL, Xiang X, Ong PS, Mitchell EQY, Syn N, Wee I, Kumar AP, Yong WP, Sethi G, Goh BC, Ho PC, Wang L.

Pharmaceutics. 2018 Nov 8;10(4). pii: E221. doi: 10.3390/pharmaceutics10040221. Review.

5.

Quantification of desoxyrhapontigenin (4-methoxyresveratrol) in rat plasma by LC-MS/MS: Application to pre-clinical pharmacokinetic study.

Dai Y, Tan ALC, Chen H, Ong PS, Xiang X, Wu J, Lin HS.

J Pharm Biomed Anal. 2018 May 10;153:95-101. doi: 10.1016/j.jpba.2018.02.026. Epub 2018 Feb 13.

PMID:
29471224
6.

Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling.

Wang L, Syn NL, Subhash VV, Any Y, Thuya WL, Cheow ESH, Kong L, Yu F, Peethala PC, Wong AL, Laljibhai HJ, Chinnathambi A, Ong PS, Ho PC, Sethi G, Yong WP, Goh BC.

Cancer Lett. 2018 Mar 28;417:152-160. doi: 10.1016/j.canlet.2017.12.030. Epub 2018 Jan 4.

PMID:
29306016
7.

Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.

Chan JC, Ong PS, Lim P, Teng PX, Chan EC.

Cancer Chemother Pharmacol. 2017 Jan;79(1):117-130. doi: 10.1007/s00280-016-3211-7. Epub 2016 Dec 9.

PMID:
27942916
8.

Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives.

Ong PS, Wang LZ, Dai X, Tseng SH, Loo SJ, Sethi G.

Front Pharmacol. 2016 Oct 25;7:395. eCollection 2016. Review.

9.

A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.

Ong PS, Wang L, Chia DM, Seah JY, Kong LR, Thuya WL, Chinnathambi A, Lau JY, Wong AL, Yong WP, Yang D, Ho PC, Sethi G, Goh BC.

Cancer Lett. 2016 Oct 10;381(1):49-57. doi: 10.1016/j.canlet.2016.07.023. Epub 2016 Jul 25.

PMID:
27461583
10.

Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development.

Wang L, Phan DD, Zhang J, Ong PS, Thuya WL, Soo R, Wong AL, Yong WP, Lee SC, Ho PC, Sethi G, Goh BC.

Oncotarget. 2016 Jul 12;7(28):44790-44802. doi: 10.18632/oncotarget.8316. Review.

11.

Quantification of the resveratrol analogs trans-2,3-dimethoxy-stilbene and trans-3,4-dimethoxystilbene in rat plasma: application to pre-clinical pharmacokinetic studies.

Ng SY, Cardullo N, Yeo SC, Spatafora C, Tringali C, Ong PS, Lin HS.

Molecules. 2014 Jul 7;19(7):9577-90. doi: 10.3390/molecules19079577.

12.

A miniaturized flow-through cell to evaluate skin permeation of endoxifen.

Mah CS, Kochhar JS, Ong PS, Kang L.

Int J Pharm. 2013 Jan 30;441(1-2):433-40. doi: 10.1016/j.ijpharm.2012.11.011. Epub 2012 Nov 19.

PMID:
23174412
13.

Quantification of trans-2,6-difluoro-4'-N,N-dimethylaminostilbene in rat plasma: application to a pharmacokinetic study.

Lin HS, Sviripa VM, Watt DS, Liu C, Xiang TX, Anderson BD, Ong PS, Ho PC.

J Pharm Biomed Anal. 2013 Jan;72:115-20. doi: 10.1016/j.jpba.2012.09.027. Epub 2012 Oct 4.

14.

Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcome.

Hoskins JM, Ong PS, Keku TO, Galanko JA, Martin CF, Coleman CA, Wolfe M, Sandler RS, McLeod HL.

PLoS One. 2012;7(7):e41954. doi: 10.1371/journal.pone.0041954. Epub 2012 Jul 27.

15.

Clinical therapeutics for phenylketonuria.

Kochhar JS, Chan SY, Ong PS, Kang L.

Drug Deliv Transl Res. 2012 Aug;2(4):223-37. doi: 10.1007/s13346-012-0067-1.

PMID:
25787029
16.

Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells.

Ong PS, Wang XQ, Lin HS, Chan SY, Ho PC.

Int J Oncol. 2012 May;40(5):1705-13. doi: 10.3892/ijo.2012.1354. Epub 2012 Feb 2.

PMID:
22328352
18.
19.

Current trends in modern pharmaceutical analysis for drug discovery.

Koh HL, Yau WP, Ong PS, Hegde A.

Drug Discov Today. 2003 Oct 1;8(19):889-97. Review.

PMID:
14554017

Supplemental Content

Loading ...
Support Center